Revenue up 38%, Q2 beats and guidance raised. Yet our stock plunged 14%. Investors still aren’t trusting, despite our results. We’ve poured our energy into Mounjaro, Zepbound, orforglipron and now I’m worried that this shockwave will cost jobs. Hope leadership is ready for the fallout.
There are no replies in this thread yet. Be the first to post a reply below: